How Jevtana May Help

JEVTANA helped men live longer and also shrank tumors after docetaxel

JEVTANA was shown to be effective in a clinical study with 755 men who:

  • Had prostate cancer that spread to other parts of the body
  • Were no longer responding to medical or surgical treatment to lower testosterone
  • Had previously been treated with a chemotherapy called docetaxel

Results seen with JEVTANA

Men Lived Longer

15.1
months*
with JEVTANA
vs
12.7
months*
with mitoxantrone

Among the 755 men in the study, 378 received JEVTANA, and 377 received mitoxantrone.

*The number of months was measured using “median overall survival.” In other words, half of the patients experienced numbers above the median and half of the patients experienced numbers below the median.

3x More Men
Had Tumors
That Shrank

14.4% with JEVTANA vs 4.4% with mitoxantrone

*The number of months was measured using "median overall survival." In other words, half of the patients experienced numbers above the median, and half of the patients experienced numbers below the median.

JEVTANA was shown to be safe and effective in a clinical study with 1,200 men looking at the risk and benefits of two different dosing options: 20 mg/m2 versus 25 mg/m2.

Please talk to your healthcare provider to learn more.


Did you know?

In the study, JEVTANA was compared to an active anti-cancer treatment called mitoxantrone. This is different from a placebo-controlled study, where one treatment is compared with placebo—a substance or treatment with no active therapeutic effect.